These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 20816370)
21. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391 [TBL] [Abstract][Full Text] [Related]
22. Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2). Nakata B; Tsuji A; Mitachi Y; Taenaka N; Kamano T; Oikawa K; Onoda N; Kambe M; Takahashi M; Shirasaka T; Morita S; Sakamoto J; Tanaka Y; Saji S; Hirakawa K Oncology; 2010; 79(5-6):337-42. PubMed ID: 21430401 [TBL] [Abstract][Full Text] [Related]
23. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer. Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528 [TBL] [Abstract][Full Text] [Related]
24. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244 [TBL] [Abstract][Full Text] [Related]
25. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages. Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311 [TBL] [Abstract][Full Text] [Related]
26. Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. Rubiales AS; del Valle ML Cancer; 1999 Apr; 85(8):1866-7. PubMed ID: 10223583 [No Abstract] [Full Text] [Related]
27. [A case of advanced rectal cancer responding to radiation therapy and chemotherapy with S-1]. Doi K; Ohchi T; Ogata K; Matsuo A; Kudoh K; Ohtao R; Sugimura H Gan To Kagaku Ryoho; 2008 Mar; 35(3):515-7. PubMed ID: 18347408 [TBL] [Abstract][Full Text] [Related]
28. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. Franck C; Malfertheiner P; Venerito M BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536214 [TBL] [Abstract][Full Text] [Related]
30. [5-fluorouracil and dihydropyrimidine dehydrogenase]. Kubota T Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775 [TBL] [Abstract][Full Text] [Related]
31. [Pancreatoduodenectomy for locally advanced ascending colon cancer after neoadjuvant chemotherapy (mFOLFOX6)]. Oono R; Enomoto N; Hosoya N; Ueda Y; Otsuki S; Motoyama K Gan To Kagaku Ryoho; 2011 Sep; 38(9):1529-31. PubMed ID: 21918356 [TBL] [Abstract][Full Text] [Related]
32. Applications of oral fluoropyrimidines in colon cancer: their role and new directions. Benson AB J Natl Compr Canc Netw; 2003 Oct; 1 Suppl 3():S-17-21. PubMed ID: 23570133 [No Abstract] [Full Text] [Related]
33. S-1: a promising new oral fluoropyrimidine derivative. Saif MW; Syrigos KN; Katirtzoglou NA Expert Opin Investig Drugs; 2009 Mar; 18(3):335-48. PubMed ID: 19243284 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Sobrero A; Guglielmi A; Grossi F; Puglisi F; Aschele C Semin Oncol; 2000 Oct; 27(5 Suppl 10):72-7. PubMed ID: 11049035 [No Abstract] [Full Text] [Related]
35. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361 [TBL] [Abstract][Full Text] [Related]
36. Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer. Ohashi M; Kanda T; Kobayashi T; Hirota M; Hayami M; Yajima K; Matsuki A; Kosugi S; Hatakeyama K; Hepatogastroenterology; 2011; 58(106):652-8. PubMed ID: 21674889 [TBL] [Abstract][Full Text] [Related]
37. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM; Pazdur R; Benner SE; Canetta R Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235 [TBL] [Abstract][Full Text] [Related]
38. [The future of loco-regional treatment for advanced gastric cancer]. Nagahama T; Ando M; Ganno H; Ami K; Fukuda A; Maruyama M Gan To Kagaku Ryoho; 2008 Nov; 35(12):2012-4. PubMed ID: 19106507 [TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704 [TBL] [Abstract][Full Text] [Related]
40. First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer. Gambill BD Clin Colorectal Cancer; 2001 May; 1(1):18-9. PubMed ID: 12445375 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]